Back to Search
Start Over
Tyrosine phosphatase PTP1B impairs presynaptic NMDA receptor-mediated plasticity in a mouse model of Alzheimer's disease.
- Source :
-
Neurobiology of disease [Neurobiol Dis] 2021 Aug; Vol. 156, pp. 105402. Date of Electronic Publication: 2021 May 24. - Publication Year :
- 2021
-
Abstract
- Mutations in the beta-amyloid protein (APP) cause familial Alzheimer's disease. In hAPP-J20 mice expressing mutant APP, pharmacological inhibition or genetic ablation of the tyrosine phosphatase PTP1B prevents CA3 hippocampus neuron loss and cognitive decline. However, how targeting PTP1B affects the cellular mechanisms underlying these cognitive deficits remains unknown. Changes in synaptic strength at the hippocampus can affect information processing for learning and memory. While prior studies have focused on post-synaptic mechanisms to account for synaptic deficits in Alzheimer's disease models, presynaptic mechanisms may also be affected. Here, using whole cell patch-clamp recording, coefficient of variation (CV) analysis suggested a profound presynaptic deficit in long-term potentiation (LTP) of CA3:CA1 synapses in hAPP-J20 mice. While the membrane-impermeable ionotropic NMDA receptor (NMDAR) blocker norketamine in the post-synaptic recording electrode had no effect on LTP, additional bath application of the ionotropic NMDAR blockers MK801 could replicate the deficit in LTP in wild type mice. In contrast to LTP, the paired-pulse ratio and short-term facilitation (STF) were aberrantly increased in hAPP-J20 mice. These synaptic deficits in hAPP-J20 mice were associated with reduced phosphorylation of NMDAR GluN2B and the synaptic vesicle recycling protein NSF (N-ethylmaleimide sensitive factor). Phosphorylation of both proteins, together with synaptic plasticity and cognitive function, were restored by PTP1B ablation or inhibition by the PTP1B-selective inhibitor Trodusquemine. Taken together, our results indicate that PTP1B impairs presynaptic NMDAR-mediated synaptic plasticity required for spatial learning in a mouse model of Alzheimer's disease. Since Trodusquemine has undergone phase 1/2 clinical trials to treat obesity, it could be repurposed to treat Alzheimer's disease.<br /> (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Alzheimer Disease drug therapy
Alzheimer Disease genetics
Animals
Cholestanes pharmacology
Cholestanes therapeutic use
Mice
Mice, Inbred C57BL
Mice, Transgenic
Neuronal Plasticity drug effects
Protein Tyrosine Phosphatase, Non-Receptor Type 1 antagonists & inhibitors
Protein Tyrosine Phosphatase, Non-Receptor Type 1 genetics
Receptors, N-Methyl-D-Aspartate genetics
Receptors, Presynaptic genetics
Spermine analogs & derivatives
Spermine pharmacology
Spermine therapeutic use
Alzheimer Disease metabolism
Neuronal Plasticity physiology
Protein Tyrosine Phosphatase, Non-Receptor Type 1 metabolism
Receptors, N-Methyl-D-Aspartate metabolism
Receptors, Presynaptic metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1095-953X
- Volume :
- 156
- Database :
- MEDLINE
- Journal :
- Neurobiology of disease
- Publication Type :
- Academic Journal
- Accession number :
- 34044147
- Full Text :
- https://doi.org/10.1016/j.nbd.2021.105402